Hypopituitarism

(redirected from hypopituitary)
Also found in: Dictionary, Medical.
Related to hypopituitary: hypopituitarism, hyperpituitarism

hypopituitarism

[‚hī·pō·pə′tü·ə·tə‚riz·əm]
(medicine)
Condition caused by insufficient secretion of pituitary hormones, especially of the adenohypophysis. Also known as panhypopituitarism.

Hypopituitarism

 

a chronic condition caused by reduced internal secretion of the pituitary body.

Hypopituitarism is manifested by insufficiency of function of the thyroid, adrenal cortex, and gonads. Trauma, tumors, infections, and hemorrhages in the area of the base of the brain can result in hypopituitarism. Hypopituitarism is manifested in arrested growth (nanism), impairment of lipometabolism, causing obesity or severe emaciation (cachexia), or underdevelopment of the sexual organs. In women with hypopituitarism, menstruation ceases and the uterus, ovaries, and mammary glands atrophy. In men the testicles and penis atrophy. Physical and mental languor, frequent dizziness, buzzing in the ears, headaches, sleepiness, susceptibility to fatigue, and a lowering of the basal metabolism are characteristic of hypopituitarism. Pituitary tumors are treated by X-ray and radiotherapy or surgical operation; other forms are treated by hormonal therapy.

L. M. GOL’BER

References in periodicals archive ?
83) Data concerning visits to the doctor, number of days in hospital, and amount of sick leave were obtained from patients included in KIMS (Pharmacia International Metabolic Database), a large pharmacoepidemiological survey of hypopituitary adults with GHD, for 6 months before GH treatment and for 6 to 12 months after the start of treatment.
Johan Svensson and colleagues in Sweden assessed the effects of growth hormone replacement therapy in a retrospective comparison of 1,411 hypopituitary adults and the normal population.
treatment of hypopituitary dwarfism) is constructed and expressed.
Krishna AY, Blevins LS: Case report: reversible gastroparesis in patients with hypopituitary disease.
In the hypopituitary rat model -- the bioassay for all currently marketed daily human growth hormone products -- Infitropin CR (InfiMed Therapeutics' sustaiined-release human growth hormone product) has shown at least equal potency compared to daily injections of the same quantity of human growth hormone.
No data are available on leukemia rates among untreated, hypopituitary patients, leaving open the possibility the leukemia link may result from an underlying genetic condition associated with hypopituitarism rather than the hGH treatment.
Humatrope therapy would be a supplement to any other hormone replacement therapy that hypopituitary patients may already be receiving (for example, estrogen, thyroid or hydrocortisone).
Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency.
Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial.